Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;99(6):561-564.
doi: 10.1111/imcb.12464. Epub 2021 May 30.

Monocytes and macrophages in severe COVID-19 - friend, foe or both?

Regine J Dress  1 , Florent Ginhoux  2   3   4
Affiliations
Comment

Monocytes and macrophages in severe COVID-19 - friend, foe or both?

Regine J Dress et al. Immunol Cell Biol. 2021 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in myeloid cell frequencies and phenotypes during severe COVID‐19. In patients with severe COVID‐19 lymphocyte frequencies within the blood decrease with time and severity of disease, while inflammatory monocyte frequencies increase, resulting in aberrant CD163hiHLA‐DRlo monocytes dominating within the blood stream. These aberrant monocytes subsequently infiltrate the airways following a CCL2 gradient, with CCL2 highly produced by activated resident airway T cells. CD163+ myeloid cells can be found aggregated in areas of alveolar damage, suggesting a contribution of these cells to the pathology of severe COVID‐19.
See this image and copyright information in PMC

Comment on

References

    1. Szabo PA, Dogra P, Gray JI, et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell‐driven lung inflammation in severe COVID‐19. Immunity 2021; 54: 797–814.e6. - PMC - PubMed
    1. Merad M, Martin JC. Pathological inflammation in patients with COVID‐19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20: 355–362. - PMC - PubMed
    1. Schulte‐Schrepping J, Reusch N, Paclik D, et al. Severe COVID‐19 is marked by a dysregulated myeloid cell compartment. Cell 2020; 182: 1419–1440.e23. - PMC - PubMed
    1. Silvin A, Chapuis N, Dunsmore G, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID‐19. Cell 2020; 182: 1401–1418.e18. - PMC - PubMed
    1. Lombardi A, Trombetta E, Cattaneo A, et al. Early phases of COVID‐19 are characterized by a reduction in lymphocyte populations and the presence of atypical monocytes. Front Immunol 2020; 11: e560330. - PMC - PubMed